posted
Well, they are working on stem cell research and it's cheap. The results of their study submitted to the FDA may propel this ahead. I say buy a few thousand shares and see what happens.
Pluristem has submitted the Pre-IND document to the Center for Biologics Evaluation and Research (CBER), Office of Cellular, Tissue and Gene Therapies, a department in the FDA. The document contains the results of additional animal model studies requested since the filing of a Pre-Pre-IND document and subsequent conference call with the FDA. The additional animal model studies' data will support Pluristem's recommendation as to the final structure of the Pre-Clinical animal study for an IND submission planned for later this year. The Pre-IND document also contains information concerning the process used to manufacture Pluristem's PLX-I product and the proposed clinical trial supporting the Company's IND.
Posts: 81 | From: Mechanicsburg, Pennsylvania | Registered: Feb 2006
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
